Evidence map›Paper›PMID 24950096›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2014

Development and validation of an LC-MS/MS method for determination of the L-type voltage-gated calcium channel/NMDA receptor antagonist NGP1-01 in mouse serum.

Harini Jogiraju, Xiang Zhou, Ashta Lakshmi Prasad Gobburi, Kiran K Pedada, Werner J Geldenhuys, Cornelis J Van der Schyf, Samuel D Crish, David J Anderson

Open access · greenAbstract readValidation Study
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Harini JogirajuDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA.
Xiang ZhouDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA.
Ashta Lakshmi Prasad GobburiDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA.
Kiran K PedadaDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA.
Werner J GeldenhuysDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, USA.
Cornelis J Van der SchyfGraduate School and Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209-8075, USA.
Samuel D CrishDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272, USA.
David J AndersonDepartment of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH 44115, USA. Electronic address: d.anderson@csuohio.edu.
Cleveland State University · USNortheast Ohio Medical University · USIdaho State University · US

Funding

Axonopathy in GlaucomaR01EY022358 · NEI · NORTHEAST OHIO MEDICAL UNIVERSITY · PI CRISH, SAMUEL D · 2012 to 2016
$1.9M
NEI NIH HHS R01 EY022358
6 · The paper itself

Abstract

NGP1-01 (8-benzylamino-8,11-oxapentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane) is a heterocyclic cage compound with multifunctional calcium channel blocking activity that has been demonstrated to be neuroprotective in several neurodegenerative models. A sensitive internal standard LC-MS/MS method was developed and validated to quantify NGP1-01 in mouse serum. The internal standard (IS) was 8-(2-phenylethylamino)-8,11-oxapentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane. Sample preparation involved a protein precipitation procedure by addition of acetonitrile. Chromatographic separation was carried out on a Phenomenex Kinetex phenyl-hexyl column (100 mm×2.1mm, 2.6 μm) employing a gradient (45% isocratic 3 min, 45-95% linear gradient 6 min, 95% isocratic 3 min) of an elution mobile phase of 5mM ammonium acetate in 100% acetonitrile mixing with an application mobile phase of 5mM ammonium acetate in 2% acetonitrile. Detection was achieved by a QTrap 5500 mass spectrometer (AB Sciex) employing electrospray ionization in the positive mode with multiple-reaction-monitoring (MRM) for NGP1-01 (m/z 266→91) and IS (m/z 280→105). The method validation was carried out in accordance with Food and Drug Administration (FDA) guidelines. The method had a linear range of at least 0.5-50 ng/mL with a correlation coefficient 0.999. The intra-assay and inter-assay precisions (%CV) were equal to or within the range of 1.0-4.3% and the accuracies (% relative error) equal to or within -2.5% to 3.4%. The analyte was stable for at least 2 months at -20°C, for at least 8h at room temperature and for at least three freeze-thaw cycles. The extraction recovery was 94.9 to 105.0%, with a %CV ≤ 9.5%. The technique was found to be free of any matrix effects as determined by experiments involving five different lots of mouse serum. Cross-talk interferences were not present. Two different gradient slope chromatography runs were done on dosed mouse serum samples to assess a possible positive error in peak area determination from in-source fragmentation of metabolites generating the same MRM transitions as the parent drug or IS. No such interference was found in the NGP1-01 peak, while a minor interference was identified in the IS peak. The optimized method was applied to the measurement of NGP1-01 in serum of dosed mice.

Indexed as

AnimalsBridged-Ring CompoundsCalcium Channel BlockersChromatography, LiquidLimit of DetectionMiceReceptors, N-Methyl-D-AspartateReproducibility of ResultsTandem Mass SpectrometryBridged-Ring CompoundsCalcium Channel BlockersNGP 1-01Receptors, N-Methyl-D-AspartateLC–MS/MSMouse serumMultifunctional drugNeuroprotective agentNGP1-01Pentacycloundecylamine

Identifiers

PMID24950096
PMCPMC4744373
OpenAlexW2080291276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.